A globally recognized allergologist specializing in urticaria, drug allergies, and angioedema, Professor Luis FC Ensina has significantly advanced clinical care, research, and education. As a Professor at the Federal University of São Paulo and coordinator of its specialized outpatient clinic, he leads Alergoalpha, a Center of Excellence for UCARE, ACARE, and ADCARE, where he has overseen over 20 clinical trials and authored more than 100 publications. A founder of the Brazilian Urticaria Network (RUBRA) and co-author of international urticaria guidelines, he has played a pivotal role in shaping global standards for allergy care. Active in organizations such as GA2LEN, AAAAI, and EAACI, he highlights the transformative potential of emerging therapies, gene therapy, and artificial intelligence to redefine allergy and immunology practice worldwide.

Prof. Paul Fockens, recipient of the 2024 UEG Lifetime Achievement Award, has profoundly shaped the field of gastrointestinal endoscopy. From pioneering techniques like endoscopic ultrasound to advancing colorectal cancer screening and minimally invasive surgeries, his transformative contributions have improved patient care globally. A dedicated mentor and leader, Prof. Fockens has also championed education and innovation through his work with UEG and beyond."

Join us as we unveil the content that made the greatest impact in 2024. From insightful Q&As and news articles to engaging podcasts, conference highlights, and medical education resources, this year has been filled with valuable content designed to support your daily practice and, ultimately, enhance patient care.

Recent advancements made in understanding the pathology of inflammatory skin conditions have enabled JAK inhibitors, initially developed for haematology over 20 years ago, to be investigated for dermatological use. In this episode, Dr William (Bill) Damsky discusses JAK inhibitors’ journey from proof-of-concept to treating a wide range of skin conditions, their future impact on rare diseases and the debate around safety.

Immuno-oncology is at the heart of Dr Hassan Abushukair’s inspiring journey from Jordan to the USA. A rising star in the field, Hassan combines clinical expertise and bioinformatics to unravel the immune system’s role in cancer, advancing precision medicine. With over 20 publications and prestigious awards, he is paving the way for innovative therapies while championing mentorship and patient-centred research.

Each year, the United European Gastroenterology (UEG) organisation awards a prestigious €50,000 Research Prize to recognise excellence in basic science, translational, or clinical research. This award supports future innovative scientific projects from inception to completion, emphasizing their transformative potential to enhance patient care. This year’s recipient, Dr. Enrique de-Madaria, Gastroenterologist and Coordinator of the Biliary-Pancreatic Unit at Dr. Balmis Hospital in Alicante, Spain, has been honoured for his groundbreaking work in fluid resuscitation for acute pancreatitis. Over the past decade, his multicentre studies—bolstered by national and international collaborations—have redefined clinical practice and established new standards of care.

IgG4-RD is a rare, chronic, relapsing condition characterized by fibroinflammatory lesions rich in CD19+ B cells, which can damage multiple organ systems and lead to organ failure.1 With no approved therapies, glucocorticoids are the primary treatment, but their long-term use is associated with adverse effects and inadequate disease control.1

Research presented at the ACG 2024 Annual Scientific Meeting found no increased risk of major adverse cardiovascular events (MACE) or venous thromboembolism (VTE) in patients with inflammatory bowel disease (IBD) treated with Janus kinase inhibitors (JAKi) compared to those receiving anti-tumor necrosis factor (anti-TNF) therapy. This retrospective cohort study, led by Dr. Saqr Alsakarneh, analyzed data from 7,480 adult patients, showing comparable MACE and VTE rates across both treatment groups, even in older adults. These findings provide reassurance regarding the cardiovascular safety of JAKi in managing IBD, although further prospective studies are needed to validate long-term outcomes.

New research presented at UEG Week 2024 has introduced a strategy that could considerably reduce the need for insulin therapy in patients with type 2 diabetes (T2D).¹ The study investigated a novel approach combining ReCET (Re-Cellularization via Electroporation Therapy) with the ...